European Society of Hypertension Congress

During the European Society of Hypertension Congress, held in Milan from 23 to 26 June, Valbiotis is currently presenting for the first time the bioavailability and mode of action clinical results of TOTUM•854 to the scientific and medical community. This innovative, plant-based active substance is developed against mild to moderate high blood pressure, to stop the worsening of the disease from the early stages. Announced in January 2023 by Valbiotis, the ex vivo clinical study demonstrated a protective effect of TOTUM•854 on the endothelial cells of the vascular wall and a reduction in the activity of ACE1, one of the main modes of action known to reduce blood pressure.
See poster